Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesOphthalmology/OptometryBlue Cross MA VEGF/complement Coverage Update | Op…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MassachusettsPolicy 092

    VEGF inhibitors and complement inhibitors for macular degeneration and diabetic eye disease

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 092 alerts

    Get alerted when Policy 092 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity and prior authorization requirements for intravitreal VEGF inhibitors and complement inhibitors used to treat neovascular AMD, diabetic eye disease, retinal vein occlusion, geographic atrophy, and related ophthalmic indications for BCBSMA commercial plans.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyVEGF inhibitors and complement inhibitors for macular degeneration and diabetic eye disease
    Policy CodePolicy 092
    Change TypeRemoved from Cotivityclarified bevacizumab PA statusadded Pavblu
    Effective DateJan 15, 2026
    Next Review Date
    Key ActionObtain prior authorization for listed non-bevacizumab agents; bevacizumab ophthalmic administrations do not require prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    Removed Eylea and Pavlu from Cotivity program.

    Clarified no prior authorization required for any bevacizumab with an ophthalmic administration.

    Updated to include Pavblu to the policy (previously added earlier).

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≈20+drug formulations listed across VEGF and complement inhibitor classes
    All requestsrequire prior authorization for listed non-bevacizumab agents
    Age ≥18default minimum age requirement in multiple coverage criteria
    Bevacizumabophthalmic bevacizumab covered under medical benefit without PA
    Individual considerationexception pathway available for atypical patients

    Medical Necessity and Coverage Criteria

    VEGF inhibitors — general medical necessity

    Bevacizumab, Beovu, Byooviz, Cimerli, Lucentis, Susvimo, and Vabysmo may be considered MEDICALLY NECESSARY when ALL of the following are met:

    VEGF-class general criteria: 1. Age 18 years and older; AND 2. Treatment failure or contraindication to Avastin (bevacizumab); AND 3. Confirmed diagnosis of one (1) of the following: a. Neovascular (Wet) Age-Related Macular Degeneration (AMD); b. Macular Edema Following Retinal Vein Occlusion (RVO); c. Diabetic Macular Edema (DME); d. Diabetic Retinopathy (DR); e. Myopic Choroidal Neovascularization (mCNV)

    Applies to the listed agents in chunk 8

    Eylea HD

    Eylea HD may be considered MEDICALLY NECESSARY when ALL of the following are met:

    Eylea HD criteria: 1. Age 18 years and older; AND 2. Treatment failure or contraindication to Avastin (bevacizumab); AND 3. Confirmed diagnosis of one (1) of the following: a. Neovascular (Wet) Age-Related Macular Degeneration (AMD); b. Diabetic Macular Edema (DME); c. Diabetic Retinopathy (DR)

    Chunk 9

    Eylea

    Eylea may be considered MEDICALLY NECESSARY when ALL of the following are met:

    Eylea criteria: 1. Age 18 years and older; AND 2. Treatment failure or contraindication to Avastin (bevacizumab); AND 3. Confirmed diagnosis of one (1) of the following: a. Neovascular (Wet) Age-Related Macular Degeneration (AMD); b. Macular Edema Following Retinal Vein Occlusion (RVO); c. Diabetic Macular Edema (DME); d. Diabetic Retinopathy (DR); e. Retinopathy of Prematurity (ROP)

    Chunk 10

    Pavblu

    Pavblu may be considered MEDICALLY NECESSARY when ALL of the following are met:

    Pavblu criteria: 1. Age 18 years and older; AND 2. Treatment failure or contraindication to Avastin (bevacizumab); AND 3. Confirmed diagnosis of one (1) of the following: a. Neovascular (Wet) Age-Related Macular Degeneration (AMD); b. Macular Edema Following Retinal Vein Occlusion (RVO); c. Diabetic Macular Edema (DME); d. Diabetic Retinopathy (DR); e. Retinopathy of Prematurity (ROP)

    Chunk 11

    Complement inhibitors — Geographic Atrophy

    Izervay or Syfovre may be considered MEDICALLY NECESSARY when ALL of the following are met:

    Complement inhibitors (GA): 1. Age 18 years and older; AND 2. Confirmed diagnosis of Geographic Atrophy (GA); AND 3. Absence of Choroidal Neovascularization (CNV) in both eyes; AND 4. Secondary to Age-Related Macular Degeneration (AMD)

    Chunk 13

    Bevacizumab ophthalmic administrations (all brands) are covered under the medical benefit and do not require prior authorization. This applies to intravitreal uses listed in the policy (for example, neovascular AMD, diabetic macular edema, diabetic retinopathy) when those uses meet applicable medical necessity criteria. Other indications or uses not listed in the agent-specific coverage criteria may be excluded unless approved through the individual consideration (exception) process.

    Use of the listed agents for indications not specified in this policy (for example, geographic atrophy or other diagnoses not shown as covered for a particular agent) does not meet the stated medical necessity criteria and therefore would not be covered as described. Providers requesting coverage for such off‑label or unlisted indications should submit an individual consideration request with supporting clinical documentation and references; these requests will be reviewed on a case‑by‑case basis.

    Coding and Age Requirements

    Coding — no explicit codes providedmixed
    N/ADocument lists package inserts and references but provides no explicit CPT/HCPCS/ICD-10 codes in the policy text.
    Minimum age requirement — default age ≥18 where specified
    Minimum ageAge 18 years and older for all listed agents
    Applies to agentsBevacizumab, Beovu, Byooviz, Cimerli, Lucentis, Susvimo, Vabysmo, Eylea HD, Eylea, Pavblu, Izervay, Syfovre
    ScopeRequired age is a precondition in each agent-specific medical necessity criterion set

    Prior Authorization, Documentation, and Provider Requirements

    Prior Authorization

    Prior authorization required for listed non‑bevacizumab agents

    Prior authorization is required for all listed non‑bevacizumab VEGF and complement inhibitor agents covered under the medical benefit; bevacizumab ophthalmic administrations do not require prior authorization.

    Step Therapy

    Step requirement: trial/failure of bevacizumab

    Coverage of non‑bevacizumab intravitreal VEGF agents generally requires prior treatment failure or a contraindication to Avastin (bevacizumab) before other agents will be considered.

    • Criteria for multiple agents state: “Treatment failure or contraindication to Avastin (bevacizumab)” as a required condition for medical necessity.

    Clinical Background

    Intravitreal Vascular Endothelial Growth Factor (VEGF) inhibitors are used to treat a range of retinal vascular and neovascular conditions including neovascular (wet) age‑related macular degeneration (AMD), diabetic macular edema (DME), macular edema secondary to retinal vein occlusion (RVO), and diabetic retinopathy (DR); certain agents are also used for retinopathy of prematurity (ROP) or myopic choroidal neovascularization (mCNV) as indicated in the agent‑specific criteria. Clinical evidence has demonstrated comparable outcomes for repackaged bevacizumab versus ranibizumab/aflibercept in many settings, which supports the policy requirement that non‑bevacizumab agents be reserved for patients who have had a treatment failure, contraindication, or are otherwise unable to use bevacizumab per the agent‑specific medical necessity criteria.

    Key Definitions

    Geographic Atrophy (GA) — definition and relation to complement inhibitors coverage
    DefinitionGeographic Atrophy (GA) = confirmed diagnosis of GA secondary to Age-Related Macular Degeneration (AMD)
    Coverage linkageComplement inhibitors (Izervay or Syfovre) may be considered medically necessary when GA is present and other criteria are met
    Key additional requirementAbsence of Choroidal Neovascularization (CNV) in both eyes is required for coverage of complement inhibitors for GA
    Minimum ageAge 18 years and older
    Neovascular (Wet) AMD — definition and relation to VEGF inhibitor coverage
    DefinitionNeovascular (Wet) AMD = AMD subtype characterized by choroidal neovascularization causing exudation and vision loss (listed as a covered diagnosis)

    Policy Revision History

    2026-01-15policy changeLatest

    Removed Eylea and Pavblu from the Cotivity program; record noted in policy history.

    2025-06editorial update

    Minor line editing to add generic name to Avastin (bevacizumab).

    2025-03clarification
    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyVEGF inhibitors and complement inhibitors for macular degeneration and diabetic eye disease
    Policy CodePolicy 092
    Change TypeRemoved from Cotivityclarified bevacizumab PA statusadded Pavblu
    Effective DateJan 15, 2026
    Next Review Date
    Key ActionObtain prior authorization for listed non-bevacizumab agents; bevacizumab ophthalmic administrations do not require prior authorization.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Age RequirementsPrior Authorization, Documentation, and Provider RequirementsClinical BackgroundKey DefinitionsPolicy Revision History
    Documentation Required

    Documentation required for prior trial/failure

    Provide documentation of prior trials and failures of formulary alternatives including the name and strength of alternatives tried, dates if available, and specifics regarding the treatment failure.

    • Include drug name and strength of bevacizumab (or other alternatives) used
    • Provide dates of therapy when available
    • Describe specifics of treatment failure or clinical reason preventing switch to formulary alternative
    Documentation Required

    Materials required for individual consideration (exceptions)

    For exception (individual consideration) requests include supporting clinical documentation such as clinical notes or statements, the name and strength of alternatives tried and failed (with specifics), peer‑reviewed literature, and references from recognized drug compendia or guidelines.

    • Clinical notes or supporting clinical statements
    • Name and strength of formulary alternatives tried and failed and specifics of failure
    • Clinical literature from reputable peer‑reviewed journals
    • References from nationally recognized compendia (e.g., AHFS‑DI, Lexi‑Drug, Clinical Pharmacology, Micromedex/Drugdex)
    • References from consensus documents or nationally sanctioned guidelines
    Denial Risk

    Denial risk if medical necessity criteria not met

    Requests for non‑bevacizumab agents that do not meet the policy’s medical necessity criteria — including the age requirement, documented trial/failure or contraindication to bevacizumab, and a covered diagnosis — risk denial.

    • Medical necessity criteria explicitly require age ≥18 and treatment failure/contraindication to bevacizumab for listed agents
    • Covered diagnoses vary by agent and must be documented (e.g., neovascular AMD, DME, RVO, DR, mCNV, ROP for select agents; GA criteria for complement inhibitors)
    Prior Authorization

    Risk of denial or delay if prior authorization is missing

    Requests for listed drugs that require prior authorization submitted without a required prior authorization may be denied or delayed.

    • Bevacizumab ophthalmic administrations are exempt from PA; all other listed agents carry PA requirements
    Coverage linkageNeovascular (Wet) AMD is a listed covered diagnosis for multiple VEGF inhibitors (e.g., bevacizumab, Beovu, Lucentis, Eylea, Pavblu)
    Common criterionTreatment failure or contraindication to Avastin (bevacizumab) is required before coverage of other VEGF agents
    Minimum ageAge 18 years and older

    Clarified that no prior authorization is required for any bevacizumab ophthalmic administration.

    2025-01addition

    Updated policy to include Pavblu as a covered agent with medical necessity criteria.

    2024-03administrative update

    Updated to require dose and frequency for Eylea to coincide with Medical claim edits.

    2024-01policy structure change

    Removed Step therapy structure and updated policy to a Prior Authorization policy; added Izervay to policy.

    2023-10step therapy update

    Moved Eylea to step 2 and added Eylea HD, Syfovre, and Bevacizumab to the policy.